Scholar Rock Holding Corporation
SRRK
Rankning i aktier
#3430
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to... Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Aktiekurs
$41.58
Senast synkroniserad: 2026-10-20
Marknadsvärde
$5.06B
Förändring (1 dag)
3.34%
Förändring (1 år)
47.62%
Land
US
Handel Scholar Rock Holding Corporation (SRRK)
Kategori
Healthcare
P/B-tal för Scholar Rock Holding Corporation (SRRK)
P/B-tal per October 2026 TTM: 20.38
Enligt Scholar Rock Holding Corporation senaste finansiella rapporter och aktiekurs är det aktuella P/B-talet (TTM) 20.38. I slutet av 2023 hade företaget ett P/B-tal på 6.34.
Historik för P/B-tal för Scholar Rock Holding Corporation från 2016 till 2026
P/B-tal vid årets slut
| År | P/B-tal | Ändra |
|---|---|---|
| 2026 (TTM) | 20.38 | 74.04% |
| 2024 | 11.71 | 84.56% |
| 2023 | 6.34 | 205.93% |
| 2022 | 2.07 | -60.88% |
| 2021 | 5.30 | -7.34% |
| 2020 | 5.72 | 77.92% |
| 2019 | 3.21 | -4.68% |
| 2018 | 3.37 | -165.04% |
| 2017 | -5.19 | -43.90% |
| 2016 | -9.24 | 0.00% |
P/B-tal för liknande företag eller konkurrenter
| Företag | P/B-tal | Skillnad i P/B-tal | Land |
|---|---|---|---|
| 6.251 | -69.33% |
US
|
|
| 13.2547 | -34.96% |
US
|
|
| 4.208 | -79.35% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -69.67% |
NL
|
